Experienced in Oppositional Defiant Disorder (ODD)

Dr. Paul E. Wylie

Psychiatry | Sleep Medicine
11219 Financial Centre Pkwy, Financial Park Place, Suite 315, 
Little Rock, AR 
Accepting New Patients
Experienced in Oppositional Defiant Disorder (ODD)
11219 Financial Centre Pkwy, Financial Park Place, Suite 315, 
Little Rock, AR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Wylie is a Psychiatrist and a Sleep Medicine provider in Little Rock, Arkansas. Dr. Wylie is rated as an Experienced provider by MediFind in the treatment of Oppositional Defiant Disorder (ODD). His top areas of expertise are Obstructive Sleep Apnea, Central Sleep Apnea, Schizophrenia, and Schizoaffective Disorder. Dr. Wylie is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Psychiatry
Sleep Medicine
Licenses
Psychiatry & Neurology in AR
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
QualChoice
  • MEDICARE MAPD
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

11219 Financial Centre Pkwy, Financial Park Place, Suite 315, Little Rock, AR 72211

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drug: BTRX-335140
Study Phase: Phase 2
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Enrollment Status: Completed
Publish Date: September 14, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Randomized Double-Blind Placebo-Controlled 4-Period Single-Dose Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to the Efficacy of AD109 in Obstructive Sleep Apnea
Phase 2 Randomized Double-Blind Placebo-Controlled 4-Period Single-Dose Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to the Efficacy of AD109 in Obstructive Sleep Apnea
Enrollment Status: Completed
Publish Date: January 31, 2023
Intervention Type: Drug, Diagnostic test
Study Drugs: AD109, Atomoxetine, R-oxybutynin
Study Phase: Phase 2
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Terminated
Publish Date: June 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
BIG4 - CPAP Educational Materials and Usage Feedback to Promote CPAP Adherence
BIG4 - CPAP Educational Materials and Usage Feedback to Promote CPAP Adherence
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Behavioral
Study Phase: Not Applicable
View 7 Less Clinical Trials

6 Total Publications

Effectiveness of an Intervention Providing Digitally Generated Personalized Feedback and Education on Adherence to Continuous Positive Airway Pressure: Randomized Controlled Trial.
Effectiveness of an Intervention Providing Digitally Generated Personalized Feedback and Education on Adherence to Continuous Positive Airway Pressure: Randomized Controlled Trial.
Journal: Journal of medical Internet research
Published: June 09, 2022
Similar Doctors
Advanced in Oppositional Defiant Disorder (ODD)
Dr. David A. Bagley
Psychiatry
Advanced in Oppositional Defiant Disorder (ODD)
Dr. David A. Bagley
Psychiatry
201 S Rose St, 
Sheridan, AR 
 (30.4 miles away)
870-917-2171
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Bagley is a Psychiatrist in Sheridan, Arkansas. Dr. Bagley is rated as an Experienced provider by MediFind in the treatment of Oppositional Defiant Disorder (ODD). His top areas of expertise are Oppositional Defiant Disorder (ODD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), and Major Depression. Dr. Bagley is currently accepting new patients.

Advanced in Oppositional Defiant Disorder (ODD)
Dr. Althea T. Conley
Psychiatry
Advanced in Oppositional Defiant Disorder (ODD)
Dr. Althea T. Conley
Psychiatry

Southeast Arkansas Behavioral Healthcare System Inc

2500 Rike Dr, 
Pine Bluff, AR 
 (42.7 miles away)
870-534-1834
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Althea Conley is a Psychiatrist in Pine Bluff, Arkansas. Dr. Conley is rated as a Distinguished provider by MediFind in the treatment of Oppositional Defiant Disorder (ODD). Her top areas of expertise are Bipolar Disorder (BPD), Major Depression, Alzheimer's Disease, and Seasonal Affective Disorder (SAD). Dr. Conley is currently accepting new patients.

Advanced in Oppositional Defiant Disorder (ODD)
Dr. Ivan O. Aldea
Child and Adolescent Psychiatry | Psychiatry
Advanced in Oppositional Defiant Disorder (ODD)
Dr. Ivan O. Aldea
Child and Adolescent Psychiatry | Psychiatry

Arkansas Psychiatric Clinic, Professional Association

4 Executive Ctr Ct, 
Little Rock, AR 
 (0.6 miles away)
501-448-0060
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ivan Aldea is a Child and Adolescent Psychiatrist and a Psychiatrist in Little Rock, Arkansas. Dr. Aldea is rated as an Advanced provider by MediFind in the treatment of Oppositional Defiant Disorder (ODD). His top areas of expertise are Autism Spectrum Disorder, Asperger's Syndrome, Seasonal Affective Disorder (SAD), and Major Depression. Dr. Aldea is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wylie's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile